Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

The purpose of the study is to evaluate how these treatments affect lung function using a special imaging technique called PET/CT, which combines positron emission tomography and computed tomography to create detailed images of the lungs. Participants will receive either the treatment or a placebo and will undergo several imaging sessions to monitor changes in lung function over time. The study aims to understand how well the lungs are working after treatment and to identify any improvements in breathing and overall lung health.

Throughout the study, participants will have regular check-ups and imaging tests to track their progress. The study will last for a period of time, during which participants will be closely monitored by healthcare professionals. The goal is to gather information that could help improve treatment options for people with pulmonary embolism in the future.

The purpose of the study is to determine if catheter-directed thrombolysis leads to better outcomes compared to standard treatment in terms of survival, prevention of new blood clots, and overall heart and lung function. The medication Actilyse will be given through an infusion directly to the blood clot, with a maximum daily dose of 20 milligrams over the course of one day.

During the study, patients will undergo various tests to monitor their heart and lung function, including computed tomography angiography to look at blood vessels in the lungs, and heart ultrasound tests to check heart function. Patients will be followed for up to two years to assess their recovery and quality of life after treatment.

The purpose of the study is to verify the effectiveness and safety of Sulodexide in reducing the chances of VTE coming back in patients aged 75 years and older who have recently experienced a first episode of DVT or PE. The study will monitor the participants over a period to see if Sulodexide can lower the risk of new blood clots by 35% compared to the placebo. Additionally, the study will assess the safety of Sulodexide by checking for any major bleeding events, aiming to show that it is not inferior to the placebo in terms of safety.

Participants in the study will take either Sulodexide or the placebo orally, in the form of soft capsules. The trial will last for a maximum of 12 months, during which the health of the participants will be closely monitored to track any new episodes of VTE, overall mortality due to VTE, and any major bleeding incidents. The study aims to provide valuable information on the potential benefits and risks of using Sulodexide for preventing recurrent VTE in elderly patients.

The purpose of the study is to determine if taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already had a clot. Participants in the study will be randomly assigned to receive either Rosuvastatin Calcium or a placebo. The study will monitor the participants over a period of time to observe any differences in the recurrence of blood clots between the two groups. The trial will also look at other health outcomes, such as the development of post-thrombotic syndrome, which is a condition that can occur after a blood clot, and other vascular events like heart attacks or strokes.

Throughout the study, participants will be regularly checked to ensure their safety and to gather information on how the medication is affecting their health. The trial is expected to continue until the end of 2027, providing valuable insights into the potential benefits of Rosuvastatin Calcium for patients with these types of blood clots.

The study will involve patients who have been diagnosed with acute pulmonary embolism and will assess the role of oxygen over a period of 30 days. Participants will receive oxygen through inhalation, which means breathing in the oxygen gas. The trial will compare the outcomes of those receiving oxygen with those who do not, to see if oxygen helps improve their condition.

The main goal of the study is to evaluate whether using oxygen can prevent serious complications such as hemodynamic collapse, which is a severe drop in blood pressure, or death within 30 days. The study will also look at other factors like the length of hospital stay and any serious side effects. The results will help understand if oxygen is beneficial for patients with acute pulmonary embolism.

The purpose of the study is to evaluate the effectiveness of a reduced dose of this thrombolytic therapy, which is a treatment that helps break down blood clots, in patients with this type of pulmonary embolism. Participants in the study will receive either the reduced dose of ACTILYSE or a placebo. The study will monitor the participants over a period of 30 days to assess the outcomes, which include the risk of death from any cause, the occurrence of hemodynamic decompensation (a condition where the heart cannot maintain adequate blood flow), or the recurrence of pulmonary embolism.

Throughout the study, researchers will also observe any severe or life-threatening bleeding events and evaluate the overall clinical benefits of the treatment. The study aims to provide valuable insights into whether a lower dose of the medication can effectively treat the condition while minimizing potential side effects. This research is important for improving treatment options for patients with intermediate-high-risk acute pulmonary embolism.

The purpose of the study is to compare these two approaches to see which is more effective in preventing further blood clots and ensuring patient safety. Participants in the study will be randomly assigned to either receive clinical surveillance or the anticoagulant treatment with Rivaroxaban. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for a period of up to 90 days, during which time participants will be monitored for any symptoms of recurrent blood clots, as well as any significant bleeding or other health issues.

Throughout the study, researchers will also assess the overall health and quality of life of the participants, as well as their use of medical resources. The goal is to determine whether clinical surveillance alone is as effective and safe as using anticoagulation therapy with Rivaroxaban for managing low-risk patients with isolated SSPE. This information will help guide future treatment decisions for this condition.

The purpose of the study is to compare these four medications to see how safe and effective they are in preventing death and hospitalizations without increasing the risk of major bleeding. The study will involve patients who have been diagnosed with atrial fibrillation, deep vein thrombosis, or pulmonary embolism. Participants will receive one of the four medications or a placebo, and their health will be monitored over time to assess the outcomes.

Throughout the study, participants will take the medication orally, as prescribed, and will be regularly checked by healthcare professionals. The study aims to provide valuable information on whether these medications are equally effective and safe for patients with the specified conditions. The trial is expected to continue until 2027, allowing for comprehensive data collection and analysis.

The purpose of the study is to evaluate whether treatment with these blood thinners affects the risk of bleeding that requires medical attention or leads to death within 30 days of starting the treatment. Participants in the study will receive either TINZAPARIN or DALTEPARIN through a subcutaneous injection, which means the medication is injected under the skin. The study will monitor patients over a period of time to observe any major bleeding events or other health outcomes.

Throughout the study, researchers will track various health indicators, such as the need for blood transfusions, the occurrence of pulmonary embolism (a blockage in the lung’s blood vessels), and any signs of heparin-induced thrombocytopenia (a condition where the blood has a lower than normal number of platelets). The study will also look at overall survival rates and the length of hospital stays. This information will help determine the safety and effectiveness of these blood thinners in treating patients with venous thromboembolism.

The medications being studied include INNOHEP (tinzaparin sodium), COUMADINE (warfarin sodium), Eliquis (apixaban), FRAGMINE (dalteparin sodium), Arixtra (fondaparinux sodium), SINTROM (acenocoumarol), HEPARINE CHOAY (heparin sodium), KARDEGIC (d,l-lysine acetylsalicylate), CALCIPARINE (heparin calcium), LOVENOX (enoxaparin sodium), Xarelto (rivaroxaban), and Plavix (clopidogrel). Some participants will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The purpose of the study is to determine if using full-dose anticoagulant therapy alone reduces the risk of significant bleeding compared to using it in combination with antiplatelet therapy. Participants will be monitored for up to 12 months to assess the occurrence of bleeding and other related health events. The study aims to provide insights into the safest and most effective treatment approach for patients with acute VTE who are also taking antiplatelet medications for other heart-related conditions.

The purpose of the study is to compare the quality and accuracy of the images produced by using three different amounts of the iodinated contrast: 20 mL, 30 mL, and 40 mL. Participants will be randomly assigned to receive one of these three amounts during their CT scan. The study aims to determine which amount provides the best images for diagnosing pulmonary embolism. The trial will measure how well the contrast highlights the blood vessels in the lungs and how accurately it helps detect blood clots.

Participants in the study will undergo a pulmonary CT angiography scan, where the contrast is injected into a vein, and images are taken to assess the blood flow in the lungs. The study will evaluate the images to see how well the different amounts of contrast work in identifying pulmonary embolism. This research will help improve the diagnosis of this condition by finding the most effective way to use the contrast during the scan.

The purpose of the study is to compare the effectiveness of these treatments in reducing the amount of clot in the lungs. Participants in the study will receive one of these treatments and will be monitored to see how well the treatment works in reducing the clot and improving their condition. The study will also look at other factors such as any bleeding complications, the length of hospital stay, and the overall quality of life after treatment.

Throughout the study, participants will undergo various assessments to track their progress, including tests to measure their ability to breathe and walk, as well as their overall heart function. The study aims to provide valuable information on the best treatment approach for patients with intermediate high-risk pulmonary embolism, helping to improve outcomes and quality of life for those affected by this condition.